1 Study Coverage 1.1 Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Introduction 1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Outlook 2017 VS 2022 VS 2028 1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028 1.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028 1.3 Alpha 1 Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Alpha 1 Antitrypsin Deficiency Treatment in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Alpha 1 Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics 1.4.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends 1.4.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers 1.4.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges 1.4.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Alpha 1 Antitrypsin Deficiency Treatment by Indication 2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Segment by Indication 2.1.1 Augmentation Therapy 2.1.2 Cystic Fibrosis(CF) 2.1.3 Non-CF Bronchiectasis(NCFB) 2.1.4 Diabetes 2.1.5 Other 2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017, 2022 & 2028) 2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028) 2.4 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017, 2022 & 2028) 2.5 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028) 3 Alpha 1 Antitrypsin Deficiency Treatment by End Users 3.1 Alpha 1 Antitrypsin Deficiency Treatment Market Segment by End Users 3.1.1 COPD 3.1.2 Cystic Fibrosis(CF) 3.1.3 Non-CF Bronchiectasis(NCFB) 3.1.4 Diabetes 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017, 2022 & 2028) 3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028) 3.4 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017, 2022 & 2028) 3.5 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028) 4 Global Alpha 1 Antitrypsin Deficiency Treatment Competitor Landscape by Company 4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Company 4.1.1 Top Global Alpha 1 Antitrypsin Deficiency Treatment Companies Ranked by Revenue (2021) 4.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Player (2017-2022) 4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Concentration Ratio (CR) 4.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Alpha 1 Antitrypsin Deficiency Treatment in 2021 4.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Alpha 1 Antitrypsin Deficiency Treatment Headquarters, Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type 4.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Headquarters and Area Served 4.3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Companies Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Alpha 1 Antitrypsin Deficiency Treatment Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Company 4.5.1 Top Alpha 1 Antitrypsin Deficiency Treatment Players in United States, Ranked by Revenue (2021) 4.5.2 United States Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2020, 2021 & 2022) 5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region 5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2028) 5.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017-2022 5.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028 6.1.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 United States 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 China Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.3 Europe 6.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028 6.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028 6.4.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 UAE 7 Company Profiles 7.1 Pfizer 7.1.1 Pfizer Company Details 7.1.2 Pfizer Business Overview 7.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.1.5 Pfizer Recent Development 7.2 GlaxoSmithKline 7.2.1 GlaxoSmithKline Company Details 7.2.2 GlaxoSmithKline Business Overview 7.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.2.5 GlaxoSmithKline Recent Development 7.3 AstraZeneca 7.3.1 AstraZeneca Company Details 7.3.2 AstraZeneca Business Overview 7.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.3.5 AstraZeneca Recent Development 7.4 Boehringer Ingelheim 7.4.1 Boehringer Ingelheim Company Details 7.4.2 Boehringer Ingelheim Business Overview 7.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.4.5 Boehringer Ingelheim Recent Development 7.5 Teva Pharmaceutical Industries 7.5.1 Teva Pharmaceutical Industries Company Details 7.5.2 Teva Pharmaceutical Industries Business Overview 7.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.5.5 Teva Pharmaceutical Industries Recent Development 7.6 Takeda 7.6.1 Takeda Company Details 7.6.2 Takeda Business Overview 7.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.6.5 Takeda Recent Development 7.7 Baxter 7.7.1 Baxter Company Details 7.7.2 Baxter Business Overview 7.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.7.5 Baxter Recent Development 7.8 Grifols 7.8.1 Grifols Company Details 7.8.2 Grifols Business Overview 7.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.8.5 Grifols Recent Development 7.9 CSL Behring 7.9.1 CSL Behring Company Details 7.9.2 CSL Behring Business Overview 7.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.9.5 CSL Behring Recent Development 7.10 Kamada Ltd 7.10.1 Kamada Ltd Company Details 7.10.2 Kamada Ltd Business Overview 7.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.10.5 Kamada Ltd Recent Development 7.11 Chiesi Pharmaceuticals 7.11.1 Chiesi Pharmaceuticals Company Details 7.11.2 Chiesi Pharmaceuticals Business Overview 7.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.11.5 Chiesi Pharmaceuticals Recent Development 7.12 Kedrion Group 7.12.1 Kedrion Group Company Details 7.12.2 Kedrion Group Business Overview 7.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.12.5 Kedrion Group Recent Development 7.13 Vertex Pharmaceuticals 7.13.1 Vertex Pharmaceuticals Company Details 7.13.2 Vertex Pharmaceuticals Business Overview 7.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.13.5 Vertex Pharmaceuticals Recent Development 7.14 ProMetic Life Sciences 7.14.1 ProMetic Life Sciences Company Details 7.14.2 ProMetic Life Sciences Business Overview 7.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction 7.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 7.14.5 ProMetic Life Sciences Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Alpha 1 Antitrypsin Deficiency Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Alpha 1 Antitrypsin Deficiency Treatment Market Trends Table 3. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers Table 4. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges Table 5. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints Table 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Alpha 1 Antitrypsin Deficiency Treatment Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Player, 2017-2022 Table 13. Global Alpha 1 Antitrypsin Deficiency Treatment Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021) Table 15. Top Players of Alpha 1 Antitrypsin Deficiency Treatment in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Alpha 1 Antitrypsin Deficiency Treatment Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Alpha 1 Antitrypsin Deficiency Treatment Players in United States Market, Ranking by Revenue (2021) Table 20. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Pfizer Company Details Table 31. Pfizer Business Overview Table 32. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Table 33. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 34. Pfizer Recent Development Table 35. GlaxoSmithKline Company Details Table 36. GlaxoSmithKline Business Overview Table 37. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Table 38. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 39. GlaxoSmithKline Recent Development Table 40. AstraZeneca Company Details Table 41. AstraZeneca Business Overview Table 42. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Table 43. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 44. AstraZeneca Recent Development Table 45. Boehringer Ingelheim Company Details Table 46. Boehringer Ingelheim Business Overview Table 47. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Table 48. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 49. Boehringer Ingelheim Recent Development Table 50. Teva Pharmaceutical Industries Company Details Table 51. Teva Pharmaceutical Industries Business Overview Table 52. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Table 53. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 54. Teva Pharmaceutical Industries Recent Development Table 55. Takeda Company Details Table 56. Takeda Business Overview Table 57. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Table 58. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 59. Takeda Recent Development Table 60. Baxter Company Details Table 61. Baxter Business Overview Table 62. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Table 63. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 64. Baxter Recent Development Table 65. Grifols Company Details Table 66. Grifols Business Overview Table 67. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Table 68. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 69. Grifols Recent Development Table 70. CSL Behring Company Details Table 71. CSL Behring Business Overview Table 72. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Table 73. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 74. CSL Behring Recent Development Table 75. Kamada Ltd Company Details Table 76. Kamada Ltd Business Overview Table 77. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Table 78. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 79. Kamada Ltd Recent Development Table 80. Chiesi Pharmaceuticals Company Details Table 81. Chiesi Pharmaceuticals Business Overview Table 82. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Table 83. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 84. Chiesi Pharmaceuticals Recent Development Table 85. Kedrion Group Company Details Table 86. Kedrion Group Business Overview Table 87. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Table 88. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 89. Kedrion Group Recent Development Table 90. Vertex Pharmaceuticals Company Details Table 91. Vertex Pharmaceuticals Business Overview Table 92. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Table 93. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 94. Vertex Pharmaceuticals Recent Development Table 95. ProMetic Life Sciences Company Details Table 96. ProMetic Life Sciences Business Overview Table 97. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Table 98. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 99. ProMetic Life Sciences Recent Development Table 100. Research Programs/Design for This Report Table 101. Key Data Information from Secondary Sources Table 102. Key Data Information from Primary Sources List of Figures Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Product Picture Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size 2017-2028 (US$ Million) Figure 4. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size 2017-2028 (US$ Million) Figure 6. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share in Global 2017-2028 Figure 7. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered Figure 8. Product Picture of Augmentation Therapy Figure 9. Product Picture of Cystic Fibrosis(CF) Figure 10. Product Picture of Non-CF Bronchiectasis(NCFB) Figure 11. Product Picture of Diabetes Figure 12. Product Picture of Other Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication in 2022 & 2028 Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028) & (US$ Million) Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028) Figure 16. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication in 2022 & 2028 Figure 17. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028) & (US$ Million) Figure 18. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028) Figure 19. Product Picture of COPD Figure 20. Product Picture of Cystic Fibrosis(CF) Figure 21. Product Picture of Non-CF Bronchiectasis(NCFB) Figure 22. Product Picture of Diabetes Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users in 2022 & 2028 Figure 24. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028) & (US$ Million) Figure 25. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028) Figure 26. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users in 2022 & 2028 Figure 27. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028) & (US$ Million) Figure 28. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028) Figure 29. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 30. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 33. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. France Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 39. China Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. India Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. China Taiwan Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Indonesia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Thailand Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Malaysia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 49. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 53. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 56. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 57. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 58. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 59. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 60. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 61. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 62. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 63. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 64. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 65. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 66. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 67. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 68. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 69. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 70. Bottom-up and Top-down Approaches for This Report Figure 71. Data Triangulation Figure 72. Key Executives Interviewed

Pfizer GlaxoSmithKline AstraZeneca Boehringer Ingelheim Teva Pharmaceutical Industries Takeda Baxter Grifols CSL Behring Kamada Ltd Chiesi Pharmaceuticals Kedrion Group Vertex Pharmaceuticals ProMetic Life Sciences